Health Condition 1: O- Medical and Surgical
Conditions
Interventions
Intervention1: Preeclamptic pregnant patients with magnesium sulfate therapy undergoing cesarean delivery using spinal block: Titrated dose of carbetocin according to sequential allocation design
intravenous at time of fetal delivery, dose of 20 -140 microgram depending on blinded allocation
Control Intervention1: Preeclamptic pregnant patients without magnesium sulfate therapy undergoing cesa
intravenous at time of fetal delivery, dose of 20 to 140 microgram depending on blinded allocation
Sponsors
University College of Medical Sciences and GTBH
Eligibility
Inclusion criteria
Inclusion criteria: Non-laboring parturients, with preeclampsia (with or without magnesium sulfate therapy scheduled for cesarean delivery under spinal block
Exclusion criteria
Exclusion criteria: Patient refusal, presence of active labor (defined as cervical dilatation of 4 cm or more), preoperative use of oxytocin, or other conditions predisposing to PPH i.e., history of previous PPH, chorioamnionitis, macrosomia, more than two previous uterine surgery, previous history of bleeding disorders, and presence of abnormal placentation/uterine fibroid; as well as use of general anesthesia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The ED90 dose (dose effective in 90% population) for satisfactory uterine tone as judged by the obstetricianTimepoint: 2 minutes after carbetocin injection, and then till end of surgery. | — |
Secondary
| Measure | Time frame |
|---|---|
| Carbetocin associated side effects like hypotension, tachycardiaTimepoint: From administration of carbetocin to 10 minutes later. | — |
Countries
India
Contacts
Public ContactDr Rabinsan S
University College of Medical Sciences and GTB Hospital
Outcome results
None listed